Wendy Kohrt
Concepts (669)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 45 | 2024 | 493 | 6.450 |
Why?
| | Exercise | 68 | 2024 | 2219 | 4.630 |
Why?
| | Body Composition | 54 | 2024 | 694 | 4.260 |
Why?
| | Bone and Bones | 16 | 2021 | 322 | 3.200 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 118 | 3.040 |
Why?
| | Postmenopause | 31 | 2020 | 394 | 3.040 |
Why?
| | Estrogens | 21 | 2024 | 368 | 2.780 |
Why?
| | Menopause | 13 | 2022 | 328 | 2.740 |
Why?
| | Bone Resorption | 7 | 2022 | 81 | 2.490 |
Why?
| | Estradiol | 18 | 2024 | 515 | 2.470 |
Why?
| | Calcium | 7 | 2021 | 1197 | 2.120 |
Why?
| | Premenopause | 11 | 2020 | 129 | 2.080 |
Why?
| | Estrogen Replacement Therapy | 16 | 2019 | 144 | 2.050 |
Why?
| | Gonadotropin-Releasing Hormone | 9 | 2024 | 217 | 1.990 |
Why?
| | Exercise Therapy | 19 | 2025 | 489 | 1.950 |
Why?
| | Endothelium, Vascular | 12 | 2026 | 959 | 1.820 |
Why?
| | Energy Metabolism | 16 | 2024 | 936 | 1.820 |
Why?
| | Estrogens, Conjugated (USP) | 9 | 2017 | 52 | 1.710 |
Why?
| | Glucose | 14 | 2025 | 1051 | 1.690 |
Why?
| | Collagen Type I | 13 | 2021 | 145 | 1.680 |
Why?
| | Walking | 11 | 2021 | 549 | 1.680 |
Why?
| | Parkinson Disease | 16 | 2025 | 613 | 1.630 |
Why?
| | Resistance Training | 9 | 2024 | 186 | 1.620 |
Why?
| | Trigger Points | 3 | 2025 | 15 | 1.540 |
Why?
| | Calcium, Dietary | 7 | 2017 | 52 | 1.530 |
Why?
| | Tension-Type Headache | 2 | 2025 | 11 | 1.460 |
Why?
| | Lactic Acid | 8 | 2025 | 295 | 1.370 |
Why?
| | Middle Aged | 130 | 2026 | 36821 | 1.350 |
Why?
| | Adipose Tissue | 25 | 2022 | 646 | 1.350 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 49 | 1.340 |
Why?
| | Aging | 30 | 2026 | 1992 | 1.340 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 41 | 1.340 |
Why?
| | Femur Neck | 8 | 2020 | 62 | 1.310 |
Why?
| | Lumbar Vertebrae | 11 | 2021 | 259 | 1.310 |
Why?
| | Aged | 115 | 2026 | 26514 | 1.210 |
Why?
| | Female | 183 | 2026 | 80076 | 1.210 |
Why?
| | Ovary | 4 | 2024 | 236 | 1.190 |
Why?
| | Insulin | 26 | 2022 | 2526 | 1.180 |
Why?
| | Peptides | 12 | 2021 | 1003 | 1.140 |
Why?
| | Bicycling | 9 | 2014 | 119 | 1.120 |
Why?
| | Humans | 238 | 2026 | 147293 | 1.120 |
Why?
| | Homeostasis | 7 | 2019 | 651 | 1.110 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 109 | 1.100 |
Why?
| | Cardiovascular Diseases | 15 | 2026 | 2218 | 1.090 |
Why?
| | Lipolysis | 6 | 2014 | 44 | 1.090 |
Why?
| | Superficial Back Muscles | 3 | 2025 | 16 | 1.070 |
Why?
| | Muscle, Skeletal | 18 | 2025 | 1798 | 1.050 |
Why?
| | Oxygen Consumption | 32 | 2025 | 721 | 1.020 |
Why?
| | Absorptiometry, Photon | 19 | 2024 | 277 | 0.970 |
Why?
| | Obesity | 21 | 2024 | 3149 | 0.960 |
Why?
| | Testosterone | 9 | 2026 | 417 | 0.940 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 383 | 0.920 |
Why?
| | Sleep Deprivation | 5 | 2022 | 207 | 0.910 |
Why?
| | Adiposity | 5 | 2018 | 533 | 0.910 |
Why?
| | Adipocytes | 6 | 2025 | 223 | 0.900 |
Why?
| | Vascular Stiffness | 6 | 2024 | 488 | 0.900 |
Why?
| | Vasodilation | 9 | 2025 | 522 | 0.890 |
Why?
| | Physical Endurance | 19 | 2015 | 279 | 0.860 |
Why?
| | Motor Activity | 11 | 2015 | 719 | 0.850 |
Why?
| | Insulin Resistance | 12 | 2025 | 1253 | 0.830 |
Why?
| | Sleep | 7 | 2022 | 895 | 0.830 |
Why?
| | Follicle Stimulating Hormone | 6 | 2024 | 266 | 0.820 |
Why?
| | Adult | 91 | 2026 | 41405 | 0.810 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 120 | 0.810 |
Why?
| | Frail Elderly | 6 | 2013 | 136 | 0.810 |
Why?
| | Male | 134 | 2026 | 73950 | 0.800 |
Why?
| | Muscle Strength | 9 | 2024 | 336 | 0.800 |
Why?
| | Weight Loss | 11 | 2024 | 867 | 0.780 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 43 | 0.760 |
Why?
| | Sweating | 2 | 2019 | 43 | 0.740 |
Why?
| | Glycerol | 8 | 2013 | 90 | 0.720 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 201 | 0.710 |
Why?
| | Regional Blood Flow | 4 | 2025 | 514 | 0.700 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 166 | 0.700 |
Why?
| | Leptin | 8 | 2025 | 249 | 0.690 |
Why?
| | Double-Blind Method | 13 | 2018 | 2080 | 0.690 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 63 | 0.680 |
Why?
| | Brachial Artery | 8 | 2025 | 209 | 0.670 |
Why?
| | Bone Remodeling | 6 | 2022 | 71 | 0.660 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 15 | 0.650 |
Why?
| | Weight-Bearing | 7 | 2017 | 187 | 0.650 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 79 | 0.640 |
Why?
| | Exercise Test | 18 | 2024 | 636 | 0.610 |
Why?
| | Sex Factors | 10 | 2024 | 2136 | 0.600 |
Why?
| | Skin | 4 | 2019 | 759 | 0.590 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 284 | 0.590 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 72 | 0.580 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 347 | 0.570 |
Why?
| | Activities of Daily Living | 7 | 2020 | 449 | 0.560 |
Why?
| | Osteoporosis | 10 | 2024 | 239 | 0.560 |
Why?
| | Headache Disorders | 1 | 2018 | 19 | 0.550 |
Why?
| | Physical Fitness | 9 | 2014 | 209 | 0.550 |
Why?
| | Biomarkers | 17 | 2026 | 4351 | 0.540 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 567 | 0.540 |
Why?
| | Massage | 1 | 2018 | 42 | 0.540 |
Why?
| | Heart Rate | 20 | 2025 | 860 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2024 | 1776 | 0.520 |
Why?
| | Weight Gain | 3 | 2011 | 566 | 0.510 |
Why?
| | Immunoglobulin G | 3 | 2021 | 901 | 0.500 |
Why?
| | Health | 3 | 2017 | 82 | 0.500 |
Why?
| | Leuprolide | 2 | 2017 | 21 | 0.480 |
Why?
| | Hot Temperature | 1 | 2019 | 396 | 0.480 |
Why?
| | Abdomen | 9 | 2005 | 142 | 0.480 |
Why?
| | Blood Glucose | 22 | 2013 | 2359 | 0.470 |
Why?
| | Ibuprofen | 2 | 2021 | 87 | 0.460 |
Why?
| | Microdialysis | 7 | 2025 | 56 | 0.460 |
Why?
| | Osteogenesis | 5 | 2020 | 205 | 0.460 |
Why?
| | Exercise Tolerance | 4 | 2025 | 289 | 0.460 |
Why?
| | Dietary Supplements | 2 | 2017 | 586 | 0.450 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 199 | 0.450 |
Why?
| | Glucose Tolerance Test | 12 | 2013 | 361 | 0.450 |
Why?
| | Medroxyprogesterone Acetate | 5 | 2003 | 33 | 0.450 |
Why?
| | Aged, 80 and over | 24 | 2019 | 8430 | 0.440 |
Why?
| | Hypogonadism | 4 | 2024 | 93 | 0.440 |
Why?
| | Antibodies | 1 | 2017 | 398 | 0.440 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 34 | 0.430 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2973 | 0.430 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 11 | 0.430 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 143 | 0.420 |
Why?
| | Young Adult | 21 | 2026 | 14437 | 0.410 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 38 | 0.410 |
Why?
| | Health Status | 4 | 2020 | 839 | 0.410 |
Why?
| | Perimenopause | 4 | 2022 | 69 | 0.410 |
Why?
| | Body Weight | 14 | 2024 | 976 | 0.400 |
Why?
| | Thigh | 3 | 2010 | 48 | 0.400 |
Why?
| | Running | 9 | 2015 | 234 | 0.380 |
Why?
| | Saliva | 2 | 2005 | 252 | 0.380 |
Why?
| | Femur | 6 | 2018 | 261 | 0.380 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 163 | 0.380 |
Why?
| | Deuterium | 6 | 2019 | 102 | 0.370 |
Why?
| | Carotid Arteries | 6 | 2024 | 208 | 0.360 |
Why?
| | Cognition Disorders | 2 | 2015 | 551 | 0.360 |
Why?
| | Sweat | 4 | 2019 | 52 | 0.360 |
Why?
| | Hydrocortisone | 3 | 2018 | 300 | 0.340 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 571 | 0.340 |
Why?
| | Hormone Antagonists | 1 | 2011 | 33 | 0.340 |
Why?
| | Quality of Life | 8 | 2022 | 3246 | 0.340 |
Why?
| | Baroreflex | 2 | 2022 | 57 | 0.340 |
Why?
| | Analysis of Variance | 11 | 2018 | 1302 | 0.330 |
Why?
| | Adipose Tissue, Brown | 2 | 2024 | 60 | 0.330 |
Why?
| | Lipids | 7 | 2026 | 723 | 0.330 |
Why?
| | Treatment Outcome | 18 | 2022 | 11947 | 0.330 |
Why?
| | Cognition | 3 | 2013 | 1286 | 0.330 |
Why?
| | Physical Education and Training | 14 | 1996 | 70 | 0.330 |
Why?
| | Procollagen | 3 | 2020 | 24 | 0.330 |
Why?
| | Osteocalcin | 5 | 2022 | 38 | 0.330 |
Why?
| | Hip | 6 | 2012 | 57 | 0.320 |
Why?
| | Women's Health | 4 | 2024 | 317 | 0.320 |
Why?
| | Body Mass Index | 10 | 2019 | 2470 | 0.320 |
Why?
| | Ovariectomy | 5 | 2025 | 166 | 0.310 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 181 | 0.310 |
Why?
| | Glucose Intolerance | 5 | 2001 | 142 | 0.310 |
Why?
| | Disability Evaluation | 5 | 2013 | 312 | 0.310 |
Why?
| | Vasodilator Agents | 1 | 2012 | 330 | 0.300 |
Why?
| | Gravitation | 1 | 2009 | 22 | 0.300 |
Why?
| | Acetaminophen | 1 | 2012 | 269 | 0.300 |
Why?
| | Bone Density Conservation Agents | 2 | 2024 | 82 | 0.300 |
Why?
| | HIV Infections | 8 | 2020 | 3235 | 0.300 |
Why?
| | Sex Characteristics | 10 | 2024 | 799 | 0.300 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.290 |
Why?
| | Adolescent | 17 | 2026 | 22825 | 0.290 |
Why?
| | Menstrual Cycle | 2 | 2013 | 145 | 0.290 |
Why?
| | Cross-Sectional Studies | 15 | 2026 | 6011 | 0.290 |
Why?
| | Alkaline Phosphatase | 3 | 2021 | 145 | 0.290 |
Why?
| | Osteoarthritis | 2 | 2015 | 204 | 0.280 |
Why?
| | Prospective Studies | 17 | 2026 | 8164 | 0.280 |
Why?
| | Heart Failure | 4 | 2024 | 2334 | 0.280 |
Why?
| | Progesterone Congeners | 3 | 2003 | 8 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1224 | 0.280 |
Why?
| | Physical Exertion | 6 | 2001 | 205 | 0.280 |
Why?
| | Dyslipidemias | 1 | 2010 | 185 | 0.270 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 440 | 0.270 |
Why?
| | Oxidative Stress | 6 | 2026 | 1368 | 0.270 |
Why?
| | Case-Control Studies | 8 | 2025 | 3660 | 0.270 |
Why?
| | Urine | 3 | 2004 | 64 | 0.270 |
Why?
| | Hematopoietic Stem Cells | 4 | 2025 | 435 | 0.260 |
Why?
| | Pain Measurement | 6 | 2018 | 569 | 0.260 |
Why?
| | Pain Threshold | 3 | 2018 | 72 | 0.260 |
Why?
| | Sports | 5 | 2020 | 216 | 0.260 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 45 | 0.250 |
Why?
| | Circadian Rhythm | 4 | 2020 | 514 | 0.250 |
Why?
| | Body Water | 2 | 2004 | 23 | 0.240 |
Why?
| | Risk Factors | 13 | 2026 | 11017 | 0.240 |
Why?
| | Peptide Fragments | 3 | 2020 | 698 | 0.240 |
Why?
| | Area Under Curve | 6 | 2013 | 334 | 0.240 |
Why?
| | Triglycerides | 4 | 2011 | 529 | 0.240 |
Why?
| | Amenorrhea | 1 | 2026 | 35 | 0.240 |
Why?
| | Fractures, Bone | 4 | 2016 | 433 | 0.240 |
Why?
| | Menstruation | 1 | 2026 | 44 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3952 | 0.240 |
Why?
| | Postural Balance | 6 | 2015 | 254 | 0.230 |
Why?
| | Sirtuins | 1 | 2026 | 50 | 0.230 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 14 | 0.220 |
Why?
| | Heart Ventricles | 2 | 2020 | 767 | 0.220 |
Why?
| | Cardiac Output | 5 | 2023 | 179 | 0.220 |
Why?
| | Blood Coagulation | 1 | 2007 | 274 | 0.220 |
Why?
| | Water | 2 | 2019 | 452 | 0.220 |
Why?
| | Cholesterol | 4 | 2011 | 410 | 0.220 |
Why?
| | Basal Metabolism | 1 | 2005 | 59 | 0.210 |
Why?
| | Alendronate | 1 | 2024 | 14 | 0.210 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 325 | 0.210 |
Why?
| | Diet | 8 | 2019 | 1284 | 0.210 |
Why?
| | Body Constitution | 2 | 2001 | 51 | 0.210 |
Why?
| | Physical Conditioning, Animal | 5 | 2025 | 242 | 0.210 |
Why?
| | Serum | 1 | 2004 | 58 | 0.210 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 202 | 0.210 |
Why?
| | Time Factors | 14 | 2019 | 7173 | 0.210 |
Why?
| | Regression Analysis | 6 | 2011 | 1003 | 0.200 |
Why?
| | Recovery of Function | 6 | 2017 | 724 | 0.200 |
Why?
| | Blood Pressure | 10 | 2022 | 1785 | 0.200 |
Why?
| | Placebos | 4 | 2011 | 193 | 0.190 |
Why?
| | Endothelin-1 | 1 | 2025 | 181 | 0.190 |
Why?
| | HIV-1 | 4 | 2013 | 917 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 165 | 0.190 |
Why?
| | Caloric Restriction | 1 | 2024 | 133 | 0.190 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 43 | 0.190 |
Why?
| | Sports Medicine | 1 | 2004 | 120 | 0.190 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 75 | 0.190 |
Why?
| | Rats, Wistar | 1 | 2024 | 450 | 0.190 |
Why?
| | Diet, Reducing | 2 | 2001 | 91 | 0.180 |
Why?
| | Arginine | 4 | 2017 | 265 | 0.180 |
Why?
| | Cold Temperature | 2 | 2024 | 207 | 0.180 |
Why?
| | Thermogenesis | 2 | 2024 | 45 | 0.180 |
Why?
| | Intermittent Claudication | 2 | 2015 | 122 | 0.180 |
Why?
| | Torque | 2 | 2012 | 82 | 0.170 |
Why?
| | Circadian Clocks | 2 | 2019 | 59 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 318 | 0.170 |
Why?
| | Knee Joint | 6 | 2017 | 439 | 0.170 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 26 | 0.170 |
Why?
| | Vitamin D | 3 | 2020 | 405 | 0.170 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 300 | 0.170 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 141 | 0.170 |
Why?
| | Proteins | 5 | 1998 | 1024 | 0.170 |
Why?
| | Ultrasonography | 7 | 2018 | 795 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.160 |
Why?
| | Intestinal Absorption | 1 | 2001 | 103 | 0.160 |
Why?
| | Polysaccharides | 2 | 2021 | 89 | 0.160 |
Why?
| | Dexamethasone | 2 | 2018 | 368 | 0.160 |
Why?
| | Glycosylation | 2 | 2021 | 176 | 0.160 |
Why?
| | Postprandial Period | 1 | 2001 | 115 | 0.160 |
Why?
| | Muscle Proteins | 3 | 2019 | 244 | 0.160 |
Why?
| | Hip Joint | 3 | 2019 | 173 | 0.160 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 117 | 0.160 |
Why?
| | Cross-Over Studies | 3 | 2014 | 617 | 0.160 |
Why?
| | Lactates | 8 | 2012 | 82 | 0.160 |
Why?
| | Animals | 23 | 2025 | 38410 | 0.160 |
Why?
| | Interleukin-6 | 2 | 2022 | 784 | 0.160 |
Why?
| | Luteal Phase | 2 | 2014 | 51 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 394 | 0.150 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 59 | 0.150 |
Why?
| | Age Factors | 7 | 2025 | 3372 | 0.150 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1077 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
| | Research Design | 4 | 2024 | 1157 | 0.150 |
Why?
| | Endothelial Cells | 1 | 2026 | 886 | 0.150 |
Why?
| | Reference Values | 6 | 2013 | 800 | 0.150 |
Why?
| | Pilot Projects | 6 | 2020 | 1912 | 0.150 |
Why?
| | Coronary Disease | 2 | 2001 | 382 | 0.150 |
Why?
| | Myocardial Contraction | 1 | 2020 | 293 | 0.150 |
Why?
| | Mitochondria | 1 | 2026 | 1000 | 0.140 |
Why?
| | C-Reactive Protein | 3 | 2026 | 430 | 0.140 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 245 | 0.140 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 6164 | 0.140 |
Why?
| | Patient Compliance | 4 | 2015 | 591 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 54 | 0.140 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 363 | 0.140 |
Why?
| | Health Behavior | 1 | 2004 | 799 | 0.140 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 117 | 0.140 |
Why?
| | Compliance | 2 | 2018 | 50 | 0.140 |
Why?
| | Acidosis | 1 | 2019 | 107 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.140 |
Why?
| | Extracellular Fluid | 1 | 2018 | 38 | 0.140 |
Why?
| | Cortisone | 1 | 2018 | 16 | 0.140 |
Why?
| | Geographic Atrophy | 1 | 2019 | 101 | 0.140 |
Why?
| | Swimming | 2 | 1989 | 54 | 0.140 |
Why?
| | Proof of Concept Study | 1 | 2018 | 90 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 212 | 0.140 |
Why?
| | Ions | 1 | 2018 | 66 | 0.130 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.130 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 49 | 0.130 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 48 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 211 | 0.130 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 29 | 0.130 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 49 | 0.130 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 147 | 0.130 |
Why?
| | Macular Degeneration | 1 | 2019 | 196 | 0.130 |
Why?
| | Rest | 2 | 1997 | 127 | 0.130 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 248 | 0.130 |
Why?
| | Growth Hormone | 1 | 1997 | 91 | 0.130 |
Why?
| | Isotope Labeling | 1 | 2017 | 82 | 0.130 |
Why?
| | Integrin beta1 | 1 | 2017 | 33 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 34 | 0.130 |
Why?
| | Athletes | 2 | 2026 | 431 | 0.120 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 346 | 0.120 |
Why?
| | Forearm | 1 | 1997 | 141 | 0.120 |
Why?
| | Hypokinesia | 1 | 2016 | 11 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 131 | 0.120 |
Why?
| | Healthy Volunteers | 2 | 2017 | 219 | 0.120 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 207 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2019 | 2627 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 135 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 44 | 0.120 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 62 | 0.120 |
Why?
| | Hyperinsulinism | 3 | 2003 | 115 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 252 | 0.120 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 510 | 0.120 |
Why?
| | Electromyography | 2 | 2016 | 419 | 0.120 |
Why?
| | Lipid Metabolism | 3 | 1998 | 538 | 0.120 |
Why?
| | Food, Fortified | 1 | 2016 | 44 | 0.120 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 127 | 0.120 |
Why?
| | Mice | 8 | 2025 | 18491 | 0.120 |
Why?
| | Pain | 1 | 2001 | 794 | 0.120 |
Why?
| | Stroke Volume | 6 | 2023 | 658 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 19 | 0.110 |
Why?
| | Energy Intake | 5 | 2013 | 514 | 0.110 |
Why?
| | Nitric Oxide | 2 | 2017 | 892 | 0.110 |
Why?
| | Gonadotropins | 1 | 2015 | 44 | 0.110 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 25 | 0.110 |
Why?
| | Aging, Premature | 2 | 2013 | 18 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 2133 | 0.110 |
Why?
| | Injections, Intravenous | 2 | 2006 | 198 | 0.110 |
Why?
| | Muscles | 7 | 2013 | 330 | 0.110 |
Why?
| | Wrist Joint | 1 | 1995 | 73 | 0.110 |
Why?
| | Stem Cells | 2 | 2017 | 630 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 464 | 0.110 |
Why?
| | Metabolomics | 1 | 2020 | 736 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2017 | 728 | 0.100 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 192 | 0.100 |
Why?
| | Linear Models | 2 | 2008 | 852 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 6041 | 0.100 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1072 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2030 | 0.100 |
Why?
| | Accidental Falls | 2 | 2017 | 231 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2791 | 0.100 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.100 |
Why?
| | Catecholamines | 1 | 1993 | 88 | 0.100 |
Why?
| | Spine | 1 | 1995 | 184 | 0.100 |
Why?
| | Health Status Indicators | 2 | 2011 | 168 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 130 | 0.100 |
Why?
| | Neck Pain | 1 | 2013 | 35 | 0.100 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 919 | 0.100 |
Why?
| | Radiography | 2 | 2012 | 862 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 231 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 251 | 0.090 |
Why?
| | Microfluidics | 1 | 2013 | 61 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 308 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2018 | 3027 | 0.090 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 52 | 0.090 |
Why?
| | Acupressure | 1 | 2012 | 9 | 0.090 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5476 | 0.090 |
Why?
| | Mathematical Concepts | 1 | 2013 | 35 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2005 | 2017 | 0.090 |
Why?
| | Hunger | 1 | 2013 | 56 | 0.090 |
Why?
| | Life Style | 3 | 2008 | 504 | 0.090 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 21 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1046 | 0.090 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 12 | 0.090 |
Why?
| | Steroids | 1 | 2013 | 162 | 0.090 |
Why?
| | Carbon Isotopes | 2 | 2006 | 143 | 0.090 |
Why?
| | Posture | 1 | 1993 | 197 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 60 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 50 | 0.090 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 1145 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.090 |
Why?
| | Hemodynamics | 4 | 2023 | 1127 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 81 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 92 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2012 | 119 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 138 | 0.090 |
Why?
| | Meals | 1 | 2013 | 132 | 0.080 |
Why?
| | Gait | 4 | 2015 | 317 | 0.080 |
Why?
| | Incidence | 3 | 2019 | 2954 | 0.080 |
Why?
| | Oxytocics | 1 | 2011 | 15 | 0.080 |
Why?
| | Headache | 1 | 2012 | 151 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 453 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 154 | 0.080 |
Why?
| | Muscle Fatigue | 1 | 2012 | 98 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 237 | 0.080 |
Why?
| | Kinetics | 5 | 2003 | 1569 | 0.080 |
Why?
| | Cartilage, Articular | 1 | 2015 | 349 | 0.080 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1281 | 0.080 |
Why?
| | Longevity | 2 | 2024 | 178 | 0.080 |
Why?
| | Perception | 2 | 2013 | 378 | 0.080 |
Why?
| | Dinoprostone | 1 | 2011 | 180 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 528 | 0.080 |
Why?
| | Single-Blind Method | 3 | 2016 | 319 | 0.080 |
Why?
| | Parity | 1 | 2010 | 112 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 575 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 66 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 428 | 0.070 |
Why?
| | Cohort Studies | 2 | 2012 | 6099 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1415 | 0.070 |
Why?
| | Androgens | 2 | 2017 | 181 | 0.070 |
Why?
| | Carbon Dioxide | 2 | 2010 | 228 | 0.070 |
Why?
| | Efficiency | 1 | 1989 | 103 | 0.070 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 41 | 0.070 |
Why?
| | Respiration | 4 | 2015 | 208 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 59 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 873 | 0.070 |
Why?
| | Muscle Contraction | 1 | 2011 | 429 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5613 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 1162 | 0.070 |
Why?
| | Chronic Pain | 1 | 2013 | 301 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 285 | 0.070 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1599 | 0.070 |
Why?
| | Advance Care Planning | 1 | 2012 | 244 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 121 | 0.070 |
Why?
| | Spectrum Analysis | 2 | 2019 | 85 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 789 | 0.070 |
Why?
| | Executive Function | 1 | 2013 | 472 | 0.070 |
Why?
| | Dietary Fats | 4 | 2013 | 309 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2086 | 0.060 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 546 | 0.060 |
Why?
| | Low Back Pain | 1 | 2008 | 109 | 0.060 |
Why?
| | Lipoproteins, HDL | 2 | 2026 | 104 | 0.060 |
Why?
| | Norepinephrine | 2 | 2021 | 201 | 0.060 |
Why?
| | Leg | 3 | 2002 | 243 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1550 | 0.060 |
Why?
| | Oligomenorrhea | 1 | 2026 | 14 | 0.060 |
Why?
| | Carrier Proteins | 2 | 2005 | 731 | 0.060 |
Why?
| | Electric Stimulation | 1 | 2007 | 277 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2021 | 2054 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 221 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1456 | 0.060 |
Why?
| | Densitometry | 2 | 1998 | 36 | 0.060 |
Why?
| | Glycoproteins | 2 | 2021 | 358 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 165 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 200 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 41 | 0.050 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 198 | 0.050 |
Why?
| | Cell Lineage | 2 | 2017 | 381 | 0.050 |
Why?
| | Nutritional Status | 2 | 2019 | 353 | 0.050 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 72 | 0.050 |
Why?
| | Colorado | 4 | 2019 | 4591 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2142 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2024 | 268 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 874 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 104 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 64 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 394 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 430 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 43 | 0.050 |
Why?
| | Liver | 3 | 2024 | 1916 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 282 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 43 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2890 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 59 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 344 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 65 | 0.040 |
Why?
| | Preoperative Period | 2 | 2014 | 150 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2019 | 17560 | 0.040 |
Why?
| | Food Deprivation | 2 | 2000 | 28 | 0.040 |
Why?
| | Osteocytes | 1 | 2001 | 24 | 0.040 |
Why?
| | Knee | 2 | 1997 | 73 | 0.040 |
Why?
| | Eating | 2 | 2001 | 387 | 0.040 |
Why?
| | Lipoproteins | 2 | 2000 | 166 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 155 | 0.040 |
Why?
| | Movement | 2 | 2014 | 293 | 0.040 |
Why?
| | Postoperative Period | 2 | 2014 | 351 | 0.040 |
Why?
| | Survival Analysis | 2 | 2015 | 1386 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2002 | 120 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 126 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 9 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2005 | 537 | 0.040 |
Why?
| | Tibia | 2 | 2019 | 177 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 417 | 0.040 |
Why?
| | Signal Transduction | 2 | 2021 | 5272 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 494 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 75 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 244 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 422 | 0.040 |
Why?
| | Kidney | 2 | 1998 | 1511 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2197 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 173 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 85 | 0.040 |
Why?
| | Child Development | 1 | 1985 | 484 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 44 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 72 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 280 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 102 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 145 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 675 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 113 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 206 | 0.040 |
Why?
| | Radius | 1 | 2019 | 53 | 0.040 |
Why?
| | Collagen | 1 | 2001 | 460 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 225 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 260 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 38 | 0.030 |
Why?
| | Antioxidants | 1 | 2022 | 550 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2020 | 226 | 0.030 |
Why?
| | Actigraphy | 1 | 2019 | 148 | 0.030 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 61 | 0.030 |
Why?
| | North Carolina | 1 | 2018 | 134 | 0.030 |
Why?
| | Isometric Contraction | 2 | 2010 | 190 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1342 | 0.030 |
Why?
| | Administration, Topical | 1 | 2018 | 156 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 139 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 45 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 283 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 154 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1147 | 0.030 |
Why?
| | Hamstring Muscles | 1 | 2017 | 22 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1059 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 430 | 0.030 |
Why?
| | Mental Health | 2 | 2015 | 813 | 0.030 |
Why?
| | Nephrectomy | 1 | 1998 | 172 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 23 | 0.030 |
Why?
| | Blood | 2 | 1995 | 107 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 7274 | 0.030 |
Why?
| | Psychometrics | 1 | 2001 | 739 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 109 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 56 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 572 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 94 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 84 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 81 | 0.030 |
Why?
| | Joints | 1 | 1997 | 106 | 0.030 |
Why?
| | Heart | 1 | 2020 | 628 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3980 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 126 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 55 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 48 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 268 | 0.030 |
Why?
| | Child | 3 | 2024 | 22979 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 150 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 269 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 56 | 0.030 |
Why?
| | Affect | 1 | 2018 | 323 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 35 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2832 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 164 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 153 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 461 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 13 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 79 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 31 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 125 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 87 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 342 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 9 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 677 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 887 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 639 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 215 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 7 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1772 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3448 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2015 | 279 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2013 | 46 | 0.020 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 20 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2018 | 625 | 0.020 |
Why?
| | Citrates | 1 | 1993 | 41 | 0.020 |
Why?
| | Calorimetry | 1 | 2013 | 69 | 0.020 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 29 | 0.020 |
Why?
| | Epinephrine | 1 | 1993 | 160 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 176 | 0.020 |
Why?
| | Comorbidity | 1 | 1998 | 1672 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2014 | 184 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 67 | 0.020 |
Why?
| | United States | 1 | 2010 | 16313 | 0.020 |
Why?
| | Appetite | 1 | 2013 | 80 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2889 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 615 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 147 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 28 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 116 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 114 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 135 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 48 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 407 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 279 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1280 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 220 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 240 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1253 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 67 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 703 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 528 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2434 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 952 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 677 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 499 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 347 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 167 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 381 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2625 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1084 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4169 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 235 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1140 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1529 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1046 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 229 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 617 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2542 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 415 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3784 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 545 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 138 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 253 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4604 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 37 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 71 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 932 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 203 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4383 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1444 | 0.010 |
Why?
| | Aerobiosis | 1 | 1985 | 18 | 0.010 |
Why?
| | Shoes | 1 | 1985 | 19 | 0.010 |
Why?
| | Orthotic Devices | 1 | 1985 | 27 | 0.010 |
Why?
| | Neoplasms | 1 | 2001 | 2946 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 6 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 205 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2008 | 781 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 41 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2920 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 326 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 372 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 37 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 430 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1093 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 3022 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 25 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 124 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 132 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 128 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 71 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 465 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 189 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 228 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 334 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 231 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 335 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 516 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 39 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 22 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 33 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 168 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 57 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 77 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 711 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 69 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 136 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 125 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 95 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 13 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.000 |
Why?
| | C-Peptide | 1 | 1991 | 191 | 0.000 |
Why?
| | Heart Diseases | 1 | 1993 | 341 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 536 | 0.000 |
Why?
| | Fatigue | 1 | 1991 | 367 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 6 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 9 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 20 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 998 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|